Panacea, SII conducting trials to develop dengue vaccine: DG ICMR

Published On 2023-05-17 09:00 GMT   |   Update On 2024-02-13 18:09 GMT
Advertisement

New Delhi: Two companies are conducting trials to develop a dengue vaccine, Director General, Indian Council of Medical Research Dr Rajeev Bahl told on Tuesday.

According to the vaccine trials status, Panacea has done phase l/ll and the trials have been completed on 100 adults between the ages of 18 and 60 years.
The primary objective of the study is safety evaluation, immunogenicity, and viremia assessment. Now the company plans to start phase 3 randomised trials, double-blind, placebo-controlled trials on 10,335 healthy adults aged 18 to 80 yrs at 20 sites of the ICMR. These trials were approved in January 2023.
Advertisement
Dr Bahl said, "The company which was supposed to make the products three months ago could not do so. However, now the company would be ready in August. So those trials will be initiated in phase three."
"Till now we can't say anything even about efficacy as well," he said further.
According to the presentation by ICMR during press briefing another company Serum Institute of India (SII) has completed phase one trials on 60 adults with the aim of safety evaluation


Tags:    
Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News